http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3923969-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87b47a5883053f16aa1e917293a1d0f7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ffe654bcde049e19b0ca2f2a3d6139f |
| publicationDate | 2021-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3923969-A1 |
| titleOfInvention | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
| abstract | Compositions and methods are provided for treating prostate cancer (PC) in a subject comprising administering to the subject a therapeutically effective amount of a polypeptide agent that inhibits EphB4 or Ephrin B2 mediated functions. More specifically, methods are provided for use in treating PTEN deficient PC or PC that is refractory to treatment using androgen receptor (AR) targeted therapy. Importantly, a therapeutic agent, soluble EphB4, prevented tumor formation and induced tumor regression in established pre-castration and post-castration tumors. Surprisingly, androgen receptor (AR) levels also declined with therapy. PI3K isoform analysis showed downregulation of only PI3K p110 beta which directly regulates AR levels, such that AR decline was rescued with ectopic expression of PI3K beta. EphB4 is thus a novel target in prostate cancer. |
| priorityDate | 2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 504.